Jonathan Peacock

Chairman • Bluesphere Bio (a UPMC Portfolio company), UCB, and Avantor

Jonathan Peacock has been chairman at Bluesphere Bio since 2021, guiding the company to the recent opening of the first IND for a TCR therapy targeting AML based on its proprietary TCR drug discovery platform. He is currently Chairman of the Board of UCB and of Avantor, two global life science companies, and is a Board member of Real Chemistry.

Mr. Peacock previously served as Chief Financial Officer of Amgen and of Novartis Pharma AG. He was Chairman and CEO of Bellerophon Therapeutics and Chairman and co-founder of Arix Bioscience plc. In addition, he was a Board member and Audit and Finance Committee Chair of Kite Pharma until its sale to Gilead for $11.9b in 2017.

Mr. Peacock is a graduate of the University of St Andrews in Scotland.